Drugs that activate the GLP-1 receptor transformed the treatment of obesity, but biotech company Metsera contends that ...

Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S. IPO, aiming to capitalize on Wall Street's insatiable appetite for such ...

Metsera, a clinical-stage biotechnology startup that develops drugs for obesity and metabolic diseases, launched on Thursday with what it described as a “broad portfolio” of weight-loss ...

The biotech recently linked the injectable candidate to weight loss of up to 11.3% after 12 weeks in a phase 2a trial. MET-097i also demonstrated a half-life of about 15 to 16 days, which Metsera ...

Jan 30 (Reuters) - Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners ...

Like Novo Nordisk and Lilly, Metsera has been set up to develop a pipeline of weight-loss therapies based on GLP-1 receptor agonism, with a focus on peptides and peptide-antibody conjugates.

BofA initiated coverage of Metsera (MTSR) with a Buy rating and $38 price target implying over 20% share upside. Metsera is a clinical-stage ...

Goldman Sachs analyst Chris Shibutani initiated coverage of Metsera (MTSR) as an Early-Stage Biotech. Metsera is clinical-stage ...

While Metsera is offering less shares ... The biotech recently linked the injectable candidate to weight loss of up to 11.3% after 12 weeks in a phase 2a trial. Meanwhile, Maze’s final share ...

At the beginning of January, Metsera reported preliminary Phase 2a data showing the drug led to dose-dependent weight loss. At the high dose, the average placebo-adjusted weight loss from the ...

(Reuters) -Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S. IPO, aiming to capitalize on Wall Street's insatiable ...